Cerus (CERS) Corporate presentation summary

Strategic positioning and market leadership

• Leads in pathogen reduction technologies for transfused blood components, with first-mover advantage and high barriers to entry in a $7B+ addressable market.

• Recurring revenues supported by a longstanding, concentrated customer base, enabling significant SG&A leverage.

• Mission is to establish INTERCEPT as the global standard of care for transfused blood components.

Product portfolio and innovation

• INTERCEPT Blood System covers platelets, plasma, and cryoprecipitate, with ongoing development for red blood cells and next-generation INT200 illumination device.

• INTERCEPT Fibrinogen Complex (IFC) offers immediate, enriched fibrinogen supplementation for bleeding control, with a 5-day shelf life when thawed.

• INT200 device features intuitive design, compactness, and custom reporting, with CE Mark and planned FDA submission in mid-2026.

Financial performance and guidance

• Achieved record Q4 2025 product revenue of $57.8M (+14% YoY) and full-year 2025 product revenue of $206.1M (+14% YoY).

• 2025 net loss was $15.6M, but non-GAAP adjusted EBITDA was positive at $9.5M; operating cash flow reached $4.8M.

• 2026 product revenue guidance is $224M–$228M, with IFC revenue expected between $20M–$22M.